EMERSON PERIN to Follow-Up Studies
This is a "connection" page, showing publications EMERSON PERIN has written about Follow-Up Studies.
Connection Strength
0.501
-
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). Circulation. 2017 Apr 11; 135(15):1417-1428.
Score: 0.068
-
A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. Circ Res. 2015 Aug 28; 117(6):576-84.
Score: 0.061
-
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J. 2014 Jul; 168(1):88-95.e2.
Score: 0.056
-
Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J. 2012 Mar; 163(3):415-21, 421.e1.
Score: 0.048
-
Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol. 2008 Mar; 44(3):486-95.
Score: 0.036
-
Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004 Sep 14; 110(11 Suppl 1):II213-8.
Score: 0.029
-
Transendocardial injection of autologous mononuclear bone marrow cells in end-stage ischemic heart failure patients: one-year follow-up. Int J Cardiol. 2004 Jun; 95 Suppl 1:S45-6.
Score: 0.028
-
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003 May 13; 107(18):2294-302.
Score: 0.026
-
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. Am Heart J. 2018 07; 201:54-62.
Score: 0.018
-
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. Circ Res. 2018 02 02; 122(3):479-488.
Score: 0.018
-
"Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017 Dec; 194:83-91.
Score: 0.018
-
Cardiac sarcoidosis. An unusual form of acute congestive cardiomyopathy. Tex Heart Inst J. 1995; 22(3):265-7.
Score: 0.015
-
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ Res. 2015 Jan 02; 116(1):99-107.
Score: 0.015
-
CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J. 2011 Jan; 161(1):98-105.
Score: 0.011
-
Outcomes of unselected recipients of sirolimus-eluting stents: the Cypher stent U.S. post-marketing surveillance registry. J Invasive Cardiol. 2010 Feb; 22(2):48-55.
Score: 0.010
-
[Diabetic and nondiabetic patients respond differently to transendocardial injection of bone marrow mononuclear cells: findings from prospective clinical trials in "no-option" patients]. Rev Esp Cardiol. 2008 Jun; 61(6):635-9.
Score: 0.009
-
Predictors of carotid stent restenosis. Catheter Cardiovasc Interv. 2007 Apr 01; 69(5):673-82.
Score: 0.009
-
Hyperexpansion of coronary stents and clinical outcomes. Tex Heart Inst J. 2006; 33(4):437-44.
Score: 0.008
-
Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation. Tex Heart Inst J. 2004; 31(3):214-9.
Score: 0.007
-
One-year results of percutaneous myocardial revascularization for refractory angina pectoris. Am J Cardiol. 2003 Jun 01; 91(11):1342-6.
Score: 0.007
-
[Evaluation of post-intracoronary stent implant. Intravascular ultrasound versus quantitative angiography]. Arq Bras Cardiol. 1995 May; 64(5):439-46.
Score: 0.004